---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-013852"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T13:28:28.851203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M

## Summary
- Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.
- Gross margin 48% vs 46% prior year; DSO decreased 27% to 63 days.
- Adjusted EBITDA loss $0.9M, flat YoY; cash $2.9M at March 31, 2022.
- Entered $2M convertible note agreement with BroadOak Fund V, L.P. on May 5, 2022 for working capital.
- Collaboration with Twist Bioscience and Miroculus to automate NGS library prep using digital microfluidics.

## SEC filing metadata
- accession: 0001493152-22-013852
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/0001493152-22-013852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-013852
- JSON: https://secwatch.observer/filing/0001493152-22-013852.json
- Plain text: https://secwatch.observer/filing/0001493152-22-013852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.